Afrodite Lourbakos - Concepedia

Author

Afrodite Lourbakos

Monash University

Also Known As

A Lourbakos, A. Lourbakos, Afrodite Lourbakos, Afrodite Lourbakos (632521), Lourbakos, Afrodite, 1972-

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Monash University The University of Melbourne BioMarin (Netherlands)University of Georgia Newcastle University

About

Afrodite Lourbakos is an author at Monash University specializing in medicine, cell signaling, and cell biology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	569
2	Cell Biology	3	3	157
3	Public Health	1	1	81
4	Biochemistry	1	1	81
5	Cellular Physiology	1	1	81

Afrodite Lourbakos

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study Thomas Voit, Haluk Topaloğlu, Volker Straub, The Lancet Neurology Placebo-controlled Phase 2MedicineDuchenne Muscular DystrophyClinical TrialsPharmacotherapy	2014	293
Arginine-Specific Protease from<i>Porphyromonas gingivalis</i>Activates Protease-Activated Receptors on Human Oral Epithelial Cells and Induces Interleukin-6 Secretion Afrodite Lourbakos, Jan Potempa, James Travis, Infection and Immunity	2001	235
Activation of protease-activated receptors by gingipains fromPorphyromonas gingivalis leads to platelet aggregation: a new trait in microbial pathogenicity Afrodite Lourbakos, YuPing Yuan, Alison L. Jenkins, Blood	2001	231
Cleavage and activation of proteinase‐activated receptor‐2 on human neutrophils by gingipain‐R from <i>Porphyromonas gingivalis</i> Afrodite Lourbakos, Carla Chinni, Philip E. Thompson, FEBS Letters	1998	169
A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy Nathalie Goemans, Eugenio Mercuri, Hirofumi Komaki, Neuromuscular Disorders Duchenne Muscular DystrophyMedicineClinical TrialsDegenerative DiseaseAntisense Oligonucleotide	2017	119
Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study Nathalie Goemans, M. Tulinius, M. van den Hauwe, PLoS ONE	2016	88
Dystrophin quantification Karen Anthony, Virginia Arechavala‐Gomeza, Laura E. Taylor, Neurology	2014	85
Protein Hydrolysates Induce CCK Release from Enteroendocrine Cells and Act as Partial Agonists of the CCK<sub>1</sub>Receptor Martin Foltz, Patrick Ansems, Jessica Schwarz, Journal of Agricultural and Food Chemistry NutritionCellular PhysiologyGastrointestinal Peptide HormoneMolecular PharmacologyCck 1	2008	81
Expression of protease-activated receptor-2 by osteoblasts Linda Abraham, Carla Chinni, Alison L. Jenkins, Bone Protease-activated Receptor-2SclerostinSignal TransductionBone Morphogenic ProteinOsteoarthritis	2000	64
Evidence for the activation of PAR‐2 by the sperm protease, acrosin: expression of the receptor on oocytes Rosealee Smith, Alison L. Jenkins, Afrodite Lourbakos, FEBS Letters	2000	55

Page 1